BDTX News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

BD

Mkt Cap

$98.0M

Volume

459.98K

Next Earnings

November 5th

Loading chart

BD

BDTXBlack Diamond Therapeutics, Inc. Common Stock

BDTX

Pay with—

Available Balance0.00

BD

Mkt Cap

$98.8M

Volume

459.98K

Next Earnings

November 5th

Chart Financials Earnings News About Insider Filings

What's Going On With Black Diamond Therapeutics Stock Tuesday?Black Diamond Therapeutics (BDTX) stock climbed on Tuesday following the announcement of encouraging Phase 2 data for silevertinib in frontline non-small cell lung cancer patients with EGFR non-classical mutations. The company beat Q1 earnings estimates with a loss of 16 cents per share versus expected 18 cents, and holds $118.3 million in cash expected to fund operations into H2 2028. However, technical analysis shows mixed signals with the stock trading below both 20-day and 50-day moving averages, and a death cross pattern suggesting longer-term bearish sentiment.Benzinga · May 26, 2026

Black Diamond Therapeutics to Participate in Jefferies Global Healthcare ConferenceBlack Diamond Therapeutics announced positive Phase 2 results for silevertinib, its brain-penetrant EGFR inhibitor, in frontline NSCLC patients with EGFR non-classical mutations. The trial showed a preliminary median progression-free survival of 15.2 months, 60% overall response rate, and robust CNS activity with 86% CNS objective response rate. The company's CEO will present at the Jefferies Global Healthcare Conference on June 3, 2026.GlobeNewswire Inc. · May 22, 2026

Black Diamond (BDTX) Q2 Loss Narrows 47%Black Diamond Therapeutics reported a narrower net loss in Q2 2025, with improved operational efficiency and focus on silevertinib clinical development. The company completed Phase 2 trial enrollment and maintains a cash runway through Q4 2027.The Motley Fool · Aug 7, 2025

Clarus (CLAR) Q2 Loss Beats EstimatesClarus reported Q2 2025 earnings with mixed results, narrowly beating analyst expectations on revenue and adjusted net loss per share, but experiencing revenue decline and ongoing profitability challenges.The Motley Fool · Aug 1, 2025

Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology TherapyServier and Black Diamond Therapeutics have announced a global licensing agreement for BDTX-4933, a targeted oncology therapy in Phase 1 development. Servier will lead the development and commercialization of the therapy, with Black Diamond receiving an upfront payment and potential milestone and royalty payments.GlobeNewswire Inc. · Mar 19, 2025

BRAF Inhibitors Market to Register Incremental Growth During the Study Period (2020–2034) | DelveInsightThe BRAF inhibitor market is expected to grow significantly due to the increasing number of cancer patients, rise in biomarker testing, and ongoing research and development of next-generation BRAF-targeting therapies.GlobeNewswire Inc. · Jan 29, 2025

Black Diamond Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateBlack Diamond Therapeutics reported encouraging initial Phase 2 data for BDTX-1535 in patients with recurrent EGFR-mutant NSCLC. The company also presented real-world data on treatment practices and outcomes for newly diagnosed NSCLC patients with non-classical EGFR mutations. Black Diamond expects to provide clinical updates and regulatory feedback on BDTX-1535 in Q1 2025.GlobeNewswire Inc. · Nov 5, 2024

Black Diamond Therapeutics Announces Restructuring Plan to Focus Resources on BDTX-1535 and Extend Cash RunwayBlack Diamond Therapeutics is focusing its resources on advancing its lead program BDTX-1535 for EGFR-mutant non-small cell lung cancer, while deprioritizing its BDTX-4933 program. The company is implementing a restructuring plan to extend its cash runway into Q2 2026.GlobeNewswire Inc. · Oct 7, 2024

Black Diamond Therapeutics to Host Webcast Presentation of Initial Phase 2 BDTX-1535 Data in Patients With Recurrent EGFRm NSCLCBlack Diamond Therapeutics will host a webcast to disclose initial phase 2 clinical trial results for BDTX-1535 in patients with recurrent EGFRm NSCLC on September 23, 2024.GlobeNewswire Inc. · Sep 22, 2024

Black Diamond Therapeutics Presents Real-World Treatment Practices and Patient Outcomes in Newly Diagnosed NSCLC Patients with Non-Classical Mutations at the European Society for Medical Oncology (ESMO) Congress 2024Black Diamond Therapeutics presented real-world data on treatment outcomes for newly diagnosed non-small cell lung cancer (NSCLC) patients with non-classical EGFR mutations. The data showed limited benefit from current EGFR tyrosine kinase inhibitors and chemotherapy, highlighting the need for new treatments in this patient population.GlobeNewswire Inc. · Sep 14, 2024

to start trading

BD

BDTXBlack Diamond Therapeutics, Inc. Common Stock

BDTX

Pay with—

Available Balance0.00

Your PositionYou don't own any BDTX yet.

Related Tickers

Earnings